Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  IgA Nephropathy Proteinuria Signed informed consent prior to any study specific procedures 2. Male and females aged 18 years and older 3. BMI 40 kg/m2 or less 4. History of nephrotic syndrome due to IgA (confirmed from renal biopsy performed within last 5 years) 5. Protein to creatinine (PCR) ratio 2.5 g/g or more (spot urine) 6. Estimated GFR (eGFR) greater than 30 mL/min/1.73/m2 (as calculated using the abbreviated Modification of Diet in Renal Disease [MDRD] equation as per http://www.kidney.org/professionals/kdoqi/gfr_calculator.cfm). 7. Any prior course of therapy with (but not within the last 3 months): steroids, cyclophosphamide, chlorambucil, cyclosporine or tacrolimus ). If, after f/u period, it was determined that subject did not achieve a complete or partial response, subject will be eligible for this study. 8. Antihypertensive treatment including use of Angiotensin-converting enzyme inhibitors (ACEI) and/or Angiotensin receptor blockers (ARB) Unless there is a history of intolerance to ACEI or ARB therapy, the subject must be treated with at least one of these agents Treatment with ACEI and/or ARB for 3 months or more prior to Visit 1, with stable maintenance dose(s) for 30 days or more prior to Visit 1 If treated with other antihypertensive therapies, treatment duration of 30 days or more and stable maintenance dose for 7 days or more prior to Visit 1; and 9. Blood pressure determined by the average of 3 or more seated readings taken 5 minutes or more apart at Visit 1 Mean systolic blood pressure 140 mmHg or less and Mean diastolic blood pressure 80 mmHg or less. 10. Subjects must have the following laboratory results for study Hemoglobin 9 g/dL or more Platelets 100 X 10^3 cells/mu-L AST 2x ULN or less ALT 2x ULN or less  Inability or refusal to give informed consent 2. Unwillingness to receive or intolerant of SC injections of study medication 3. Use of disease modifying agent within "delayed effect" 1 month of Visit 1 with: glucorticoids, cyclophosphamide, cyclosporine, cellcept 4. Therapies and/or medications History of previous use of Acthar for treatment of nephrotic syndrome Prior sensitivity to Acthar or other porcine protein products Planned treatment with live or live attenuated vaccines once enrolled in the study 5. Chronic systemic corticosteroid use, defined as any dose of systemic corticosteroid taken for more than 4 consecutive weeks within 1 month prior to Visit 1 (use of topical, inhaled, or intra-articular corticosteroids is allowed) 6. Planned treatment with live or live attenuated vaccines once enrolled in the study. 7. Contraindication to Acthar per Prescribing Information* 8. For the purpose of this study: history of peptic ulcer is defined as 6 months or less prior to Visit 1. 9. Renal target disease exclusions* 10. Out of control or severe hypertension 11. History of Systemic Lupus Erythematosus 12. Uncontrolled Type 1 or type 2 diabetes mellitus (prior diagnosis of gestational diabetes mellitus is not an exclusion) 13. History of Deep Vein Thrombosis (DVT) 6 months or less prior to Visit 1 14. Presence of renal vein thrombosis Known current diagnosis by ultrasound, magnetic resonance imaging (MRI) or computed tomography scan Signs or symptoms consistent with occurrence of acute renal vein thrombosis (hematuria in combination with flank pain and >30% unexplained acute rise in serum creatinine) with renal vein thrombosis confirmed by ultrasound, MRI or computed tomography scan 15. Reproductive status Women who are pregnant Women who are breastfeeding Women of childbearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period, as evaluated by the Investigator (women who are not of childbearing potential are those that have a history of hysterectomy, bilateral oophorectomy, or are postmenopausal with no history of menstrual flow for 12 months or more prior to Visit 1 16. Chronic active hepatitis C or B infection 17. Known immunocompromised status, including but not limited to individuals who have undergone organ transplantation or who are known to be positive for human immunodeficiency virus 18. Undergoing or have received therapy for solid tumor malignancy 5 years or less prior to Visit 1 (with the exception of treated and cured basal cell or treated and cured squamous cell carcinoma) 19. Undergoing or have received therapy for blood malignancy 5 years or less from Visit 1 20. Cardiovascular History of or active congestive heart failure (NYHA Functional Classification Class II through IV) on http://sscts.org/ClassificationHeartFailureNYHA.aspx OR